Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The future of leukemia treatment in the elderly

John DiPersio • 5 Oct 2017
ESH 2017
Leukemia

An advanced age can limit treatment options when tackling leukemia. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA discusses treatment options for patients with leukemia who are over the age of 60, and the future applications of chemotherapy and bispecifics in this group.

More from John DiPersio

One big question with John DiPersio: what AML advance could transform frontline care in three years?
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
3:30
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
John DiPersio • 19 Sep 2025
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
1:14
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
John DiPersio • 19 Sep 2025
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
2:23
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
John DiPersio • 19 Sep 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals